CHF128.30 Novartis AG (NOVN.SW) on SIX intraday: most active stock signals momentum

Novartis AG (NOVN.SW) is trading at CHF128.30 on the SIX intraday tape on 17 Feb 2026, up 2.53% and among Switzerland’s most active names. The move follows a 1,537,929 share intraday volume spike as buyers pushed the price above the 50-day average of CHF113.15. Fundamentals remain solid with EPS CHF5.52 and PE 22.91, while the healthcare sector average PE is higher at 33.83. This intraday momentum matters for short-term traders watching liquidity and sector flows.

Market snapshot and intraday activity for NOVN.SW stock

Novartis (NOVN.SW) is trading on the SIX market in Switzerland at CHF128.30 with a day low CHF126.82 and day high CHF129.14. Volume is 1,537,929, below the 3-month average of 3,195,876, but still keeps the share among the day’s most active names.

Price is +2.53% today, reflecting positive intraday sentiment. For traders, the relVolume of 0.89 suggests active interest but not extreme crowding.

Fundamentals and valuation: NOVN.SW analysis vs sector

Novartis reports EPS CHF5.52 and a PE of 22.91, below the Healthcare sector average PE of 33.83. This indicates a relative valuation discount versus peers on a price-earnings basis.

Key ratios show a dividend yield near 2.77% and book value per share CHF24.32. The balance sheet supports investment with interest coverage 15.13 and debt-to-equity 0.80.

Technicals and trading signals for NOVN.SW stock

Short-term indicators show strong momentum: RSI 82.21 and CCI 144.51, flagging overbought conditions. MACD is positive with histogram 0.60, supporting the intraday rally.

Bollinger upper band sits at 124.49, now below the price. Traders should note ATR 2.13 for risk sizing and that overbought oscillators can mean pullbacks happen fast.

Meyka AI stock grade and model forecast for NOVN.SW

Meyka AI assigns proprietary grades to stocks based on multiple factors. Meyka AI rates NOVN.SW with a score out of 100: 78.10 giving a B+ and a suggestion: BUY. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus.

Meyka AI’s forecast model projects a quarterly target CHF127.28 and a five-year target CHF140.37, implying a near-term -0.79% and a medium-term upside of 9.41% versus the current CHF128.30. Forecasts are model-based projections and not guarantees; we are not financial advisors.

Price targets, consensus and analyst-style view for NOVN.SW

Public analyst consensus details are limited, but valuation and cashflow metrics support mid-cycle upside. Price averages show 50-day CHF113.15 and 200-day CHF102.42, both well below the current price.

Given PE 22.91 and free cash flow yield 5.34%, a realistic near-term price target range is CHF120.00–CHF135.00 depending on trial news and Sandoz performance.

Risks and catalysts affecting NOVN.SW stock trading

Regulatory approvals or trial setbacks in Innovative Medicines can swing the stock quickly. Sandoz margin recovery or generic pressure are medium-term risk drivers.

Macro and currency moves affect Swiss names. Watch upcoming earnings on 28 Apr 2026 and pipeline readouts as catalysts for bigger intraday moves.

Final Thoughts

Key takeaways on NOVN.SW stock for intraday and most-active traders: Novartis (NOVN.SW) trades at CHF128.30 on SIX with strong intraday momentum and volume placing it among the day’s most active Swiss names. Fundamentals remain robust with EPS CHF5.52, PE 22.91, and dividend yield 2.77%, while valuation sits below the sector average PE of 33.83. Technicals warn of overbought conditions (RSI 82.21), so short-term pullbacks are possible. Meyka AI’s models project a five-year target CHF140.37, an implied upside of 9.41%, and a near-term quarterly model of CHF127.28. These model outputs reflect current cash flows, sector positioning, and trend signals. Use the upcoming earnings on 28 Apr 2026 and pipeline updates as decision points. Meyka AI provides this as an AI-powered market analysis platform; forecasts are projections, not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.